Status:
UNKNOWN
'Distortion as a Predictor of ERM Surgery Outcome'
Lead Sponsor:
NHS Greater Glasgow and Clyde
Collaborating Sponsors:
Royal College of Surgeons of Edinburgh
Conditions:
Epiretinal Membrane
Distortion
Eligibility:
All Genders
18+ years
Brief Summary
Epiretinal membranes (ERM) consist of an abnormal growth of tissue across the retina and are present about 6% of people aged 50 and over. They can cause symptoms of distortion (straight lines appearin...
Detailed Description
Epiretinal membranes consist of a proliferation of fibrocellular tissue along the inner aspect of the retina. Over time, this membrane can result in anterior-posterior traction and cause disruption of...
Eligibility Criteria
Inclusion
- Idiopathic epiretinal membrane
- Patients undergoing vitrectomy and gas surgery, under local or general anaesthetic
- Able to give informed consent
- 18 years old and over
Exclusion
- Epiretinal membrane secondary to retinal detachment, uveitis or retinal vascular disease
- Previous vitreoretinal surgery
- Pre-existing ophthalmic condition which limits the patient's visual acuity (Documented BCVA 6/36 or worse)
- Pre-existing ophthalmic conditions which cause metamorphopsia (exudative ARMD, central serous retinopathy)
- VA \< 6/60
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04791631
Start Date
April 1 2021
End Date
April 1 2023
Last Update
March 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NHS Greater Glasgow and Clyde Clinical Research and Development Central Office
Paisley, United Kingdom, PA2 7DE